Notably, high GPRC5A expression correlated with poor overall survival in ovarian cancer patients, while SPARC expression showed no significant association, implicating GPRC5A in disease progression (Figure 5J, S3A, Supplementary S3). Here, GPRC5A is linked to ovarian carcinoma.